AMAG Pharmaceuticals (AMAG) was Reiterated by Deutsche Bank to “Hold” while Lowering the Price Target of the company shares to $ 35 from a previous price target of $42 . Deutsche Bank advised their investors in a research report released on May 9, 2016.
Many Wall Street Analysts have commented on AMAG Pharmaceuticals. AMAG Pharmaceuticals was Downgraded by Raymond James to ” Mkt Perform” on May 4, 2016.
On the company’s financial health, AMAG Pharmaceuticals reported $0.94 EPS for the quarter, missing the analyst consensus estimate by $ -0.13 based on the information available during the earnings call on May 3, 2016. Analyst had a consensus of $1.07. The company had revenue of $117.90 million for the quarter, compared to analysts expectations of $124.59 million. The company’s revenue was up 41.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.17 EPS.
AMAG Pharmaceuticals closed down -0.25 points or -1.24% at $19.85 with 19,67,180 shares getting traded on Friday. Post opening the session at $19.84, the shares hit an intraday low of $19.47 and an intraday high of $20.24 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Nov 10, 2015, John A. Fallon (director) purchased 3,230 shares at $31.20 per share price. According to the SEC, on Oct 2, 2015, William K Heiden (CEO) sold 2,000 shares at $39.69 per share price. On Aug 7, 2015, Frank E Thomas (President & COO) sold 15,000 shares at $66.85 per share price, according to the Form-4 filing with the securities and exchange commission.
AMAG Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company focuses on maternal health anemia and cancer supportive care. The Company markets Makena (hydroxyprogesterone caproate injection) Feraheme (ferumoxytol) Injection for Intravenous (IV) use and MuGard Mucoadhesive Oral Wound Rinse. Feraheme is an IV iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). Feraheme is approved for marketing in the United States. Makena is a drug indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. MuGard is indicated for the management of oral mucositis/stomatitis and all types of oral wounds including aphthous ulcers/canker sores and traumatic ulcers such as those caused by oral surgery or ill-fitting dentures or braces.